Dendritic cell based vaccination strategy: an evolving paradigm
/in Dendritic Cells, Glioblastoma, International Publications /von 2017-04-22 / J. Neurooncol. 2017 Jun;133(2):223-235Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer
/in Dendritic Cells, Exosome, International Publications, Pancreatic Cancer /von 2017-04-20 / Oncoimmunology 2017;6(6):e1319044Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2017-04-20 / JCI Insight 2017 Apr;2(8)Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2017-04-18 / Oncotarget 2017 Apr;8(16):27252-27262Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
/in Dendritic Cells, Glioblastoma, International Publications /von 2017-04-15 / Clin. Cancer Res. 2017 04;23(8):1898-1909Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia
/in Acute Leukemia, Dendritic Cells, International Publications /von 2017-04-14 / Cancer 2017 Aug;123(16):3061-3072Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2017-04-07 / J Hematol Oncol 2017 04;10(1):82Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2017-03-22 / J Transl Med 2017 03;15(1):64Immune and viral therapies for malignant primary brain tumors
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease Virus /von 2017-03-05 / Expert Opin Biol Ther 2017 04;17(4):457-474
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de